▎WuXiEdited by the Kant Content Team
Developing CAR-T Therapy for T-Cell Lymphoma, March Biosciences Completes $28.4 Million Series A Financing
March Biosciences today announced the successful completion of an oversubscribed $28.4 million Series A financing. The proceeds will be used to support the Phase 2 clinical development of its lead investigational program, MB-105, and further optimize the production process.
The company'sMB-105, the flagship therapy, is an autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to treat relapsed and refractory CD5-positive T-cell lymphoma. MB-105 is specifically engineered to overcome major obstacles associated with T-cell targeting, effectively addressing T-cell fratricide while maintaining potent cytotoxicity against CD5-positive tumor cells.MB-105 Demonstrates Good Safety and Durable Responses in a Phase 1 Clinical Trial for Relapsed T-cell Lymphoma Patients at Baylor College of Medicine. The company plans to initiate Phase 2 clinical trials in early 2025.
Nuclear Medicine Startup March Biosciences Completes $175 Million Series C Financing
Alpha-9 Oncology Announces Successful Completion of Oversubscribed $175 Million Series C Financing to Advance its PipelineAlpha-9 Oncology today announced the successful completion of an oversubscribed $175 million Series C financing to support the advancement of its R&D pipeline. The company has built a diversified clinical-stage and discovery-stage R&D pipeline covering both validated and innovative targets. This Series C financing will be used to support human studies for clinical-stage therapeutic candidates and to advance discovery-stage drug candidates into clinical development. Additionally, the Series C financing will also be utilized to expand R&D capabilities and continue investment in Chemistry, Manufacturing, and Controls (CMC) and the supply chain.
Alpha-9 possesses a unique set of ligands, linkers, chelators, and radioisotope technologies, all of which play critical roles in radiopharmaceutical development. Alpha-9 has optimized each component of every radiopharmaceutical to ensure selectivity, stability, and effective payload delivery.
▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.
[1] Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals. Retrieved October 23, 2024, from https://www.prnewswire.com/news-releases/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals-302283806.html[2] March Biosciences Closes Oversubscribed $28.4 Million Series A Financing. Retrieved October 23, 2024, from https://www.globenewswire.com/news-release/2024/10/23/2967726/0/en/March-Biosciences-Closes-Oversubscribed-28-4-Million-Series-A-Financing.htmlDisclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In View, Focusing on Global Biomedical Health Innovation
